Here’s a quick rundown of the process: Visit the official Python website. Navigate to the ‘Downloads’ section. Select your ...

Florida’s Burmese python problem isn’t going away anytime soon. The researchers, snake trackers, and other conservationists working to remove the giant snakes will be the first to tell you that ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

Burmese pythons — large, nonvenomous constrictor snakes — are native to South Asia, but since they were introduced to Florida, they have become one of the most destructive invasive species the state ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage ...

Recursion Pharma’s May update is the primary near-term driver of its stock. The company ended 2024 with $60M in cash, providing runway till 2027. Up Next: Wall Street trader’s 34-0 strategy goes ...

The market is viewing NVIDIA's decision to keep its 7.7 million share stake in Recursion while divesting from other AI holdings as a significant strategic move. This decision indicates NVIDIA's ...

We recently published a list of 12 Cheap AI Stocks to Buy in 2025. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other cheap AI ...